APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urinary Tract Infection Medications

Compare research editions
View pricing & licenses

Selected research

Industry Research

Urinary Tract Infection Medications Industry Research Report 2026

28 December 2025130 pages

Choose your research edition.

Industry ResearchUrinary Tract Infection Medications Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Urinary Tract Infection Medications Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Urinary Tract Infection Medications Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urinary Tract Infection Medications Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Urinary Tract Infection Medications Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Urinary Tract Infection Medications market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Urinary Tract Infection Medications is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Urinary Tract Infection Medications is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Urinary Tract Infection Medications is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Urinary Tract Infection Medications include Allecra Therapeutic, Bayer AG, Cipla Inc., Eli Lily Company, GlaxoSmithKline plc, MEDICE, Merck & Co. Inc., Novartis Ag and Novo Nordisk A/S, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Urinary Tract Infection Medications market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Urinary Tract Infection Medications Market by Company

Allecra Therapeutic

Bayer AG

Cipla Inc.

Eli Lily Company

GlaxoSmithKline plc

MEDICE

Merck & Co. Inc.

Novartis Ag

Novo Nordisk A/S

Utility Therapeutics

Northeast Pharmaceuticals

Guangxi Qingzhipin Pharmaceutical Co., Ltd.

Pfizer Inc.

Teva Pharmaceuticals

Whiteson Pharma

Urinary Tract Infection Medications Segment by Type

Cephalosporins

Penicillins

Quinolones

Sulfonamides

Furans

Others

Urinary Tract Infection Medications Segment by Application

Online Pharmacy

Hospital

Clinic

Others

Urinary Tract Infection Medications Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urinary Tract Infection Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urinary Tract Infection Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urinary Tract Infection Medications.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Urinary Tract Infection Medications manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Urinary Tract Infection Medications by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Urinary Tract Infection Medications in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Urinary Tract Infection Medications Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Urinary Tract Infection Medications Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Urinary Tract Infection Medications Sales Market Share by Manufacturers (2021-2026) Table 8. Global Urinary Tract Infection Medications Revenue of Manufacturers (2021-2026) Table 9. Global Urinary Tract Infection Medications Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Urinary Tract Infection Medications Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Urinary Tract Infection Medications Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Urinary Tract Infection Medications, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Urinary Tract Infection Medications, Product Type & Application Table 14. Global Urinary Tract Infection Medications Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Urinary Tract Infection Medications by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Allecra Therapeutic Company Information Table 19. Allecra Therapeutic Business Overview Table 20. Allecra Therapeutic Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Allecra Therapeutic Urinary Tract Infection Medications Product Portfolio Table 22. Allecra Therapeutic Recent Developments Table 23. Bayer AG Company Information Table 24. Bayer AG Business Overview Table 25. Bayer AG Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Bayer AG Urinary Tract Infection Medications Product Portfolio Table 27. Bayer AG Recent Developments Table 28. Cipla Inc. Company Information Table 29. Cipla Inc. Business Overview Table 30. Cipla Inc. Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Cipla Inc. Urinary Tract Infection Medications Product Portfolio Table 32. Cipla Inc. Recent Developments Table 33. Eli Lily Company Company Information Table 34. Eli Lily Company Business Overview Table 35. Eli Lily Company Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Eli Lily Company Urinary Tract Infection Medications Product Portfolio Table 37. Eli Lily Company Recent Developments Table 38. GlaxoSmithKline plc Company Information Table 39. GlaxoSmithKline plc Business Overview Table 40. GlaxoSmithKline plc Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. GlaxoSmithKline plc Urinary Tract Infection Medications Product Portfolio Table 42. GlaxoSmithKline plc Recent Developments Table 43. MEDICE Company Information Table 44. MEDICE Business Overview Table 45. MEDICE Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. MEDICE Urinary Tract Infection Medications Product Portfolio Table 47. MEDICE Recent Developments Table 48. Merck & Co. Inc. Company Information Table 49. Merck & Co. Inc. Business Overview Table 50. Merck & Co. Inc. Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Merck & Co. Inc. Urinary Tract Infection Medications Product Portfolio Table 52. Merck & Co. Inc. Recent Developments Table 53. Novartis Ag Company Information Table 54. Novartis Ag Business Overview Table 55. Novartis Ag Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Novartis Ag Urinary Tract Infection Medications Product Portfolio Table 57. Novartis Ag Recent Developments Table 58. Novo Nordisk A/S Company Information Table 59. Novo Nordisk A/S Business Overview Table 60. Novo Nordisk A/S Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Novo Nordisk A/S Urinary Tract Infection Medications Product Portfolio Table 62. Novo Nordisk A/S Recent Developments Table 63. Utility Therapeutics Company Information Table 64. Utility Therapeutics Business Overview Table 65. Utility Therapeutics Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Utility Therapeutics Urinary Tract Infection Medications Product Portfolio Table 67. Utility Therapeutics Recent Developments Table 68. Northeast Pharmaceuticals Company Information Table 69. Northeast Pharmaceuticals Business Overview Table 70. Northeast Pharmaceuticals Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Northeast Pharmaceuticals Urinary Tract Infection Medications Product Portfolio Table 72. Northeast Pharmaceuticals Recent Developments Table 73. Guangxi Qingzhipin Pharmaceutical Co., Ltd. Company Information Table 74. Guangxi Qingzhipin Pharmaceutical Co., Ltd. Business Overview Table 75. Guangxi Qingzhipin Pharmaceutical Co., Ltd. Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Guangxi Qingzhipin Pharmaceutical Co., Ltd. Urinary Tract Infection Medications Product Portfolio Table 77. Guangxi Qingzhipin Pharmaceutical Co., Ltd. Recent Developments Table 78. Pfizer Inc. Company Information Table 79. Pfizer Inc. Business Overview Table 80. Pfizer Inc. Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Pfizer Inc. Urinary Tract Infection Medications Product Portfolio Table 82. Pfizer Inc. Recent Developments Table 83. Teva Pharmaceuticals Company Information Table 84. Teva Pharmaceuticals Business Overview Table 85. Teva Pharmaceuticals Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Teva Pharmaceuticals Urinary Tract Infection Medications Product Portfolio Table 87. Teva Pharmaceuticals Recent Developments Table 88. Whiteson Pharma Company Information Table 89. Whiteson Pharma Business Overview Table 90. Whiteson Pharma Urinary Tract Infection Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Whiteson Pharma Urinary Tract Infection Medications Product Portfolio Table 92. Whiteson Pharma Recent Developments Table 93. Global Urinary Tract Infection Medications Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Urinary Tract Infection Medications Sales by Region (2021-2026) & (K Units) Table 95. Global Urinary Tract Infection Medications Sales Market Share by Region (2021-2026) Table 96. Global Urinary Tract Infection Medications Sales by Region (2027-2032) & (K Units) Table 97. Global Urinary Tract Infection Medications Sales Market Share by Region (2027-2032) Table 98. Global Urinary Tract Infection Medications Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Urinary Tract Infection Medications Revenue Market Share by Region (2021-2026) Table 100. Global Urinary Tract Infection Medications Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Urinary Tract Infection Medications Revenue Market Share by Region (2027-2032) Table 102. North America Urinary Tract Infection Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Urinary Tract Infection Medications Sales by Country (2021-2026) & (K Units) Table 104. North America Urinary Tract Infection Medications Sales by Country (2027-2032) & (K Units) Table 105. North America Urinary Tract Infection Medications Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Urinary Tract Infection Medications Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Urinary Tract Infection Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Urinary Tract Infection Medications Sales by Country (2021-2026) & (K Units) Table 109. Europe Urinary Tract Infection Medications Sales by Country (2027-2032) & (K Units) Table 110. Europe Urinary Tract Infection Medications Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Urinary Tract Infection Medications Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Urinary Tract Infection Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Urinary Tract Infection Medications Sales by Country (2021-2026) & (K Units) Table 114. Asia Pacific Urinary Tract Infection Medications Sales by Country (2027-2032) & (K Units) Table 115. Asia Pacific Urinary Tract Infection Medications Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Urinary Tract Infection Medications Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Urinary Tract Infection Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Urinary Tract Infection Medications Sales by Country (2021-2026) & (K Units) Table 119. South America Urinary Tract Infection Medications Sales by Country (2027-2032) & (K Units) Table 120. South America Urinary Tract Infection Medications Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Urinary Tract Infection Medications Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Urinary Tract Infection Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Urinary Tract Infection Medications Sales by Country (2021-2026) & (K Units) Table 124. Middle East and Africa Urinary Tract Infection Medications Sales by Country (2027-2032) & (K Units) Table 125. Middle East and Africa Urinary Tract Infection Medications Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Urinary Tract Infection Medications Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Urinary Tract Infection Medications Sales by Type (2021-2026) & (K Units) Table 128. Global Urinary Tract Infection Medications Sales by Type (2027-2032) & (K Units) Table 129. Global Urinary Tract Infection Medications Sales Market Share by Type (2021-2026) Table 130. Global Urinary Tract Infection Medications Sales Market Share by Type (2027-2032) Table 131. Global Urinary Tract Infection Medications Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Urinary Tract Infection Medications Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Urinary Tract Infection Medications Revenue Market Share by Type (2021-2026) Table 134. Global Urinary Tract Infection Medications Revenue Market Share by Type (2027-2032) Table 135. Global Urinary Tract Infection Medications Price by Type (2021-2026) & (US$/Unit) Table 136. Global Urinary Tract Infection Medications Price by Type (2027-2032) & (US$/Unit) Table 137. Global Urinary Tract Infection Medications Sales by Application (2021-2026) & (K Units) Table 138. Global Urinary Tract Infection Medications Sales by Application (2027-2032) & (K Units) Table 139. Global Urinary Tract Infection Medications Sales Market Share by Application (2021-2026) Table 140. Global Urinary Tract Infection Medications Sales Market Share by Application (2027-2032) Table 141. Global Urinary Tract Infection Medications Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Urinary Tract Infection Medications Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Urinary Tract Infection Medications Revenue Market Share by Application (2021-2026) Table 144. Global Urinary Tract Infection Medications Revenue Market Share by Application (2027-2032) Table 145. Global Urinary Tract Infection Medications Price by Application (2021-2026) & (US$/Unit) Table 146. Global Urinary Tract Infection Medications Price by Application (2027-2032) & (US$/Unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Urinary Tract Infection Medications Distributors List Table 150. Urinary Tract Infection Medications Customers List Table 151. Urinary Tract Infection Medications Industry Trends Table 152. Urinary Tract Infection Medications Industry Drivers Table 153. Urinary Tract Infection Medications Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Urinary Tract Infection Medications Product Image Figure 5. Global Urinary Tract Infection Medications Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Urinary Tract Infection Medications Market Size (2021-2032) & (US$ Million) Figure 7. Global Urinary Tract Infection Medications Sales (2021-2032) & (K Units) Figure 8. Global Urinary Tract Infection Medications Average Price (US$/Unit) & (2021-2032) Figure 9. Cephalosporins Product Image Figure 10. Penicillins Product Image Figure 11. Quinolones Product Image Figure 12. Sulfonamides Product Image Figure 13. Furans Product Image Figure 14. Others Product Image Figure 15. Online Pharmacy Product Image Figure 16. Hospital Product Image Figure 17. Clinic Product Image Figure 18. Others Product Image Figure 19. Global Urinary Tract Infection Medications Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Urinary Tract Infection Medications, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Urinary Tract Infection Medications Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Urinary Tract Infection Medications Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Urinary Tract Infection Medications Sales by Region in 2025 Figure 25. Global Urinary Tract Infection Medications Revenue by Region in 2025 Figure 26. North America Urinary Tract Infection Medications Market Size by Country in 2025 Figure 27. North America Urinary Tract Infection Medications Sales Market Share by Country (2021-2032) Figure 28. North America Urinary Tract Infection Medications Revenue Market Share by Country (2021-2032) Figure 29. United States Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Mexico Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Europe Urinary Tract Infection Medications Market Size by Country in 2025 Figure 33. Europe Urinary Tract Infection Medications Sales Market Share by Country (2021-2032) Figure 34. Europe Urinary Tract Infection Medications Revenue Market Share by Country (2021-2032) Figure 35. Germany Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. France Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. U.K. Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Italy Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Russia Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Spain Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Netherlands Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Switzerland Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Sweden Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Poland Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Asia Pacific Urinary Tract Infection Medications Market Size by Country in 2025 Figure 46. Asia Pacific Urinary Tract Infection Medications Sales Market Share by Country (2021-2032) Figure 47. Asia Pacific Urinary Tract Infection Medications Revenue Market Share by Country (2021-2032) Figure 48. China Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Japan Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South Korea Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. India Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Australia Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Taiwan Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. South America Urinary Tract Infection Medications Market Size by Country in 2025 Figure 57. South America Urinary Tract Infection Medications Sales Market Share by Country (2021-2032) Figure 58. South America Urinary Tract Infection Medications Revenue Market Share by Country (2021-2032) Figure 59. Brazil Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Argentina Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Chile Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Colombia Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Middle East and Africa Urinary Tract Infection Medications Market Size by Country in 2025 Figure 64. Middle East and Africa Urinary Tract Infection Medications Sales Market Share by Country (2021-2032) Figure 65. Middle East and Africa Urinary Tract Infection Medications Revenue Market Share by Country (2021-2032) Figure 66. Egypt Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. South Africa Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Israel Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Türkiye Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. GCC Countries Urinary Tract Infection Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 71. Global Urinary Tract Infection Medications Sales Market Share by Type (2021-2032) Figure 72. Global Urinary Tract Infection Medications Revenue Market Share by Type (2021-2032) Figure 73. Global Urinary Tract Infection Medications Price (US$/Unit) by Type (2021-2032) Figure 74. Global Urinary Tract Infection Medications Sales Market Share by Application (2021-2032) Figure 75. Global Urinary Tract Infection Medications Revenue Market Share by Application (2021-2032) Figure 76. Global Urinary Tract Infection Medications Price (US$/Unit) by Application (2021-2032) Figure 77. Urinary Tract Infection Medications Value Chain Figure 78. Urinary Tract Infection Medications Production Mode & Process Figure 79. Direct Comparison with Distribution Share Figure 80. Distributors Profiles Figure 81. Urinary Tract Infection Medications Industry Opportunities and Challenges

Scope & coverage.

Types
  • Cephalosporins
  • Penicillins
  • Quinolones
  • Sulfonamides
  • Furans
  • Others
Applications
  • Online Pharmacy
  • Hospital
  • Clinic
  • Others
Companies covered
  • Allecra Therapeutic
  • Bayer AG
  • Cipla Inc.
  • Eli Lily Company
  • GlaxoSmithKline plc
  • MEDICE
  • Merck & Co. Inc.
  • Novartis Ag
  • Novo Nordisk A/S
  • Utility Therapeutics
  • Northeast Pharmaceuticals
  • Guangxi Qingzhipin Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Teva Pharmaceuticals
  • Whiteson Pharma

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Urinary Tract Infection Medications Market Size (2021-2032)
  4. 2.2.2 Global Urinary Tract Infection Medications Sales (2021-2032)
  5. 2.2.3 Global Urinary Tract Infection Medications Market Average Price (2021-2032)
  6. 2.3 Urinary Tract Infection Medications by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Cephalosporins
  9. 2.3.3 Penicillins
  10. 2.3.4 Quinolones
  11. 2.3.5 Sulfonamides
  12. 2.3.6 Furans
  13. 2.3.7 Others
  14. 2.4 Urinary Tract Infection Medications by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Online Pharmacy
  17. 2.4.3 Hospital
  18. 2.4.4 Clinic
  19. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Urinary Tract Infection Medications Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Urinary Tract Infection Medications Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Urinary Tract Infection Medications Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Urinary Tract Infection Medications Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Urinary Tract Infection Medications Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Urinary Tract Infection Medications, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Urinary Tract Infection Medications, Product Type & Application
  8. 3.8 Global Manufacturers of Urinary Tract Infection Medications, Established Date
  9. 3.9 Global Urinary Tract Infection Medications Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Allecra Therapeutic
  2. 4.1.1 Allecra Therapeutic Company Information
  3. 4.1.2 Allecra Therapeutic Business Overview
  4. 4.1.3 Allecra Therapeutic Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Allecra Therapeutic Urinary Tract Infection Medications Product Portfolio
  6. 4.1.5 Allecra Therapeutic Recent Developments
  7. 4.2 Bayer AG
  8. 4.2.1 Bayer AG Company Information
  9. 4.2.2 Bayer AG Business Overview
  10. 4.2.3 Bayer AG Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bayer AG Urinary Tract Infection Medications Product Portfolio
  12. 4.2.5 Bayer AG Recent Developments
  13. 4.3 Cipla Inc.
  14. 4.3.1 Cipla Inc. Company Information
  15. 4.3.2 Cipla Inc. Business Overview
  16. 4.3.3 Cipla Inc. Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Cipla Inc. Urinary Tract Infection Medications Product Portfolio
  18. 4.3.5 Cipla Inc. Recent Developments
  19. 4.4 Eli Lily Company
  20. 4.4.1 Eli Lily Company Company Information
  21. 4.4.2 Eli Lily Company Business Overview
  22. 4.4.3 Eli Lily Company Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Eli Lily Company Urinary Tract Infection Medications Product Portfolio
  24. 4.4.5 Eli Lily Company Recent Developments
  25. 4.5 GlaxoSmithKline plc
  26. 4.5.1 GlaxoSmithKline plc Company Information
  27. 4.5.2 GlaxoSmithKline plc Business Overview
  28. 4.5.3 GlaxoSmithKline plc Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 GlaxoSmithKline plc Urinary Tract Infection Medications Product Portfolio
  30. 4.5.5 GlaxoSmithKline plc Recent Developments
  31. 4.6 MEDICE
  32. 4.6.1 MEDICE Company Information
  33. 4.6.2 MEDICE Business Overview
  34. 4.6.3 MEDICE Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 MEDICE Urinary Tract Infection Medications Product Portfolio
  36. 4.6.5 MEDICE Recent Developments
  37. 4.7 Merck & Co. Inc.
  38. 4.7.1 Merck & Co. Inc. Company Information
  39. 4.7.2 Merck & Co. Inc. Business Overview
  40. 4.7.3 Merck & Co. Inc. Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Merck & Co. Inc. Urinary Tract Infection Medications Product Portfolio
  42. 4.7.5 Merck & Co. Inc. Recent Developments
  43. 4.8 Novartis Ag
  44. 4.8.1 Novartis Ag Company Information
  45. 4.8.2 Novartis Ag Business Overview
  46. 4.8.3 Novartis Ag Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Novartis Ag Urinary Tract Infection Medications Product Portfolio
  48. 4.8.5 Novartis Ag Recent Developments
  49. 4.9 Novo Nordisk A/S
  50. 4.9.1 Novo Nordisk A/S Company Information
  51. 4.9.2 Novo Nordisk A/S Business Overview
  52. 4.9.3 Novo Nordisk A/S Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Novo Nordisk A/S Urinary Tract Infection Medications Product Portfolio
  54. 4.9.5 Novo Nordisk A/S Recent Developments
  55. 4.10 Utility Therapeutics
  56. 4.10.1 Utility Therapeutics Company Information
  57. 4.10.2 Utility Therapeutics Business Overview
  58. 4.10.3 Utility Therapeutics Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Utility Therapeutics Urinary Tract Infection Medications Product Portfolio
  60. 4.10.5 Utility Therapeutics Recent Developments
  61. 4.11 Northeast Pharmaceuticals
  62. 4.11.1 Northeast Pharmaceuticals Company Information
  63. 4.11.2 Northeast Pharmaceuticals Business Overview
  64. 4.11.3 Northeast Pharmaceuticals Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Northeast Pharmaceuticals Urinary Tract Infection Medications Product Portfolio
  66. 4.11.5 Northeast Pharmaceuticals Recent Developments
  67. 4.12 Guangxi Qingzhipin Pharmaceutical Co., Ltd.
  68. 4.12.1 Guangxi Qingzhipin Pharmaceutical Co., Ltd. Company Information
  69. 4.12.2 Guangxi Qingzhipin Pharmaceutical Co., Ltd. Business Overview
  70. 4.12.3 Guangxi Qingzhipin Pharmaceutical Co., Ltd. Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Guangxi Qingzhipin Pharmaceutical Co., Ltd. Urinary Tract Infection Medications Product Portfolio
  72. 4.12.5 Guangxi Qingzhipin Pharmaceutical Co., Ltd. Recent Developments
  73. 4.13 Pfizer Inc.
  74. 4.13.1 Pfizer Inc. Company Information
  75. 4.13.2 Pfizer Inc. Business Overview
  76. 4.13.3 Pfizer Inc. Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Pfizer Inc. Urinary Tract Infection Medications Product Portfolio
  78. 4.13.5 Pfizer Inc. Recent Developments
  79. 4.14 Teva Pharmaceuticals
  80. 4.14.1 Teva Pharmaceuticals Company Information
  81. 4.14.2 Teva Pharmaceuticals Business Overview
  82. 4.14.3 Teva Pharmaceuticals Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Teva Pharmaceuticals Urinary Tract Infection Medications Product Portfolio
  84. 4.14.5 Teva Pharmaceuticals Recent Developments
  85. 4.15 Whiteson Pharma
  86. 4.15.1 Whiteson Pharma Company Information
  87. 4.15.2 Whiteson Pharma Business Overview
  88. 4.15.3 Whiteson Pharma Urinary Tract Infection Medications Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Whiteson Pharma Urinary Tract Infection Medications Product Portfolio
  90. 4.15.5 Whiteson Pharma Recent Developments
5 Global Urinary Tract Infection Medications Market Scenario by Region
  1. 5.1 Global Urinary Tract Infection Medications Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Urinary Tract Infection Medications Sales by Region: 2021-2032
  3. 5.2.1 Global Urinary Tract Infection Medications Sales by Region: 2021-2026
  4. 5.2.2 Global Urinary Tract Infection Medications Sales by Region: 2027-2032
  5. 5.3 Global Urinary Tract Infection Medications Revenue by Region: 2021-2032
  6. 5.3.1 Global Urinary Tract Infection Medications Revenue by Region: 2021-2026
  7. 5.3.2 Global Urinary Tract Infection Medications Revenue by Region: 2027-2032
  8. 5.4 North America Urinary Tract Infection Medications Market Facts & Figures by Country
  9. 5.4.1 North America Urinary Tract Infection Medications Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Urinary Tract Infection Medications Sales by Country (2021-2032)
  11. 5.4.3 North America Urinary Tract Infection Medications Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Urinary Tract Infection Medications Market Facts & Figures by Country
  16. 5.5.1 Europe Urinary Tract Infection Medications Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Urinary Tract Infection Medications Sales by Country (2021-2032)
  18. 5.5.3 Europe Urinary Tract Infection Medications Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Urinary Tract Infection Medications Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Urinary Tract Infection Medications Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Urinary Tract Infection Medications Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Urinary Tract Infection Medications Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Urinary Tract Infection Medications Market Facts & Figures by Country
  41. 5.7.1 South America Urinary Tract Infection Medications Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Urinary Tract Infection Medications Sales by Country (2021-2032)
  43. 5.7.3 South America Urinary Tract Infection Medications Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Urinary Tract Infection Medications Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Urinary Tract Infection Medications Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Urinary Tract Infection Medications Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Urinary Tract Infection Medications Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Urinary Tract Infection Medications Sales by Type (2021-2032)
  2. 6.1.1 Global Urinary Tract Infection Medications Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Urinary Tract Infection Medications Sales Market Share by Type (2021-2032)
  4. 6.2 Global Urinary Tract Infection Medications Revenue by Type (2021-2032)
  5. 6.2.1 Global Urinary Tract Infection Medications Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Urinary Tract Infection Medications Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Urinary Tract Infection Medications Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Urinary Tract Infection Medications Sales by Application (2021-2032)
  2. 7.1.1 Global Urinary Tract Infection Medications Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Urinary Tract Infection Medications Sales Market Share by Application (2021-2032)
  4. 7.2 Global Urinary Tract Infection Medications Revenue by Application (2021-2032)
  5. 7.2.1 Global Urinary Tract Infection Medications Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Urinary Tract Infection Medications Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Urinary Tract Infection Medications Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Urinary Tract Infection Medications Value Chain Analysis
  2. 8.1.1 Urinary Tract Infection Medications Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Urinary Tract Infection Medications Production Mode & Process
  5. 8.2 Urinary Tract Infection Medications Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Urinary Tract Infection Medications Distributors
  8. 8.2.3 Urinary Tract Infection Medications Customers
9 Global Urinary Tract Infection Medications Analyzing Market Dynamics
  1. 9.1 Urinary Tract Infection Medications Industry Trends
  2. 9.2 Urinary Tract Infection Medications Industry Drivers
  3. 9.3 Urinary Tract Infection Medications Industry Opportunities and Challenges
  4. 9.4 Urinary Tract Infection Medications Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst